Ponatinib-d8

CAT: 0804-HY-12047SSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-12047SSize:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ponatinib-d8 (AP24534-d8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
CAS Number
[1562993-37-6]
Product Name Alternative
AP24534-d8
UNSPSC
12352005
Hazard Statement
H302+H312+H332-H315-H319
Target
Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.91
Solubility
1 M HCl : 50mg/mL (ultrasonic; adjust pH to 1 with HCl) |10 mM in DMSO|DMSO : 25mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=CC=C(CN2C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C2([2H])[2H])C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C5C=CC=NN54)=C3
Molecular Formula
C29H19D8F3N6O
Molecular Weight
540.61
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16 (5), 401-412.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
PDGFRα; VEGFR2/KDR/Flk-1

Popular Products